Descrizione del progetto
Approcci personalizzati per un’assistenza sanitaria migliore
Con l’obiettivo di migliorare la sicurezza generale dei pazienti, il progetto di ricerca SafePolyMed, finanziato dall’UE, intende sviluppare strumenti innovativi al fine di aiutare medici e farmacisti a definire, valutare e gestire meglio le interazioni farmaco-farmaco-gene. L’apprendimento automatico basato su grandi serie di dati reali individuerà i pazienti a rischio, mentre strumenti di dosaggio di precisione basati su modelli ottimizzeranno i trattamenti per i pazienti e le misure di esito riportate dai pazienti valuteranno il successo del trattamento. I centri di gestione dei farmaci fungeranno da poli per pazienti e personale sanitario, al fine di scoprire le cause di fondo degli scarsi esiti dei trattamenti e delineare piani di trattamento maggiormente personalizzati. Tramite l’istruzione e la responsabilizzazione della cittadinanza affinché partecipi attivamente all’auto-documentazione della propria terapia, il progetto punta a migliorare la comunicazione tra pazienti e personale medico, fornendo un accesso equo a un’assistenza sanitaria innovativa, sostenibile e di alta qualità in Europa.
Obiettivo
Polypharmacy, multimorbidity and genetic heterogeneity can affect drug efficacy, raise the risk for adverse drug reactions (ADRs) and increase healthcare costs. ADRs are among the leading causes of death in developed countries and a major cause of hospitalization. Drug-drug interactions (DDIs) and drug-gene interactions (DGIs) are highly interconnected and require a holistic approach to improve safety of our citizens. However, investigations on real-life drug-drug-gene interactions (DDGIs) in clinical trials are unfeasible due to combinatorial explosion, high costs and ethical concerns. Hence, significant knowledge gaps exist. Furthermore, the lack of participation in managing their conditions might be excessively demanding for polymedicated and multimorbid citizens. SafePolyMed will develop a novel and innovative framework to define, assess and manage DDGIs for physicians and individual patients resulting in education and empowerment of citizens as well as in reduced healthcare costs by improving patient safety. The main objectives of SafePolyMed are (1) development of a novel, evidence-based risk scoring system using machine learning on large real-world datasets to identify patients at risk; (2) identification and validation of patient reported outcome measures for multifactorial patient safety in collaboration with European patient organizations;
(3) development of an electronic tool to empower patients by allowing them to properly manage their therapies, check for and educate about DD(G)Is and collect their patient reported outcomes; (4) mathematical modelling of clinically relevant compounds to derive individualized dose adaptations for safe and effective dose regimens in case of DDGIs, accessible via a web-based decision support system with tailored information for either citizens or physicians and (5) validation of the developed safety tools in a ?proof-of-principle? study including representative patient cohorts from different European clinical sites.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug safety
- medical and health scienceshealth sciencespersonalized medicine
- medical and health sciencesbasic medicinepharmacology and pharmacyadverse drug reactions
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
- natural sciencesmathematicsapplied mathematicsmathematical model
Programma(i)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.6 - Health Care Systems
Meccanismo di finanziamento
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinatore
66123 Saarbrucken
Germania